| Literature DB >> 28100224 |
Bipransh Kumar Tiwary1,2, Somit Dutta3, Priyankar Dey3, Mossaraf Hossain4, Anoop Kumar5, Sony Bihani5, Ashis Kumar Nanda6, Tapas Kumar Chaudhuri3, Ranadhir Chakraborty7.
Abstract
BACKGROUND: Lagerstroemia speciosa (L.) Pers. has medicinal importance. Bioactive phytochemicals isolated from different parts of L. speciosa, have revealed hypoglycemic, antibacterial, anti-inflammatory, antioxidant and hepato protective properties. Despite one report from Philippines detailing the use of L. speciosa as curative for fever and as well as diuretic, there is no experimental evidence about the hepatoprotective activity of the flower extracts.Entities:
Keywords: Antioxidant activity; CCl4-intoxicated; GC-MS; Hepatoprotective; Lagerstroemia speciosa
Mesh:
Substances:
Year: 2017 PMID: 28100224 PMCID: PMC5241977 DOI: 10.1186/s12906-016-1495-0
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Free radical scavanging activity of Lagerstroemia flower extract (LFE). a Total antioxidant assay; b DPPH radical scavenging activity; c Singlet oxygen scavenging activity; d Superoxide radical scavenging activity; e Peroxynitrite radical scavenging activity; f Nitric oxide scavenging activity; g (i) and (ii). Fe chelation activity; h Hydroxy radical scavenging; i Hypocholorous radical scavenging activity; j Erythrocyte membrane stabilizing activity; and k Reducing power assay. Paired ‘t’ test was done to interpret significant difference between effect of LFE and the known standard; ***, p < 0.001; **, p < 0.01; and *, p < 0.05
Half maximal inhibitory concentration (IC50) value of LFE and standards compounds for different free radical scavenging assays
| S.No | Assay | Standard compound | Calculated IC50 Standard | Calculated IC50 LFE | 2-sample t test |
|---|---|---|---|---|---|
| 1 | DPPH | Ascorbic acid | 11.30 ± 1.23 | 3.23 ± 0.7 | 0.002 |
| 2 | Superoxide radical | Quercetin | 63.83 ± 2.5 | 65.57 ± 3.4 | 0.52 |
| 3 | Singlet Oxygen | Lipoic acid | 131.21 ± 8.3 | 162.72 ± 4.2 | 0.02 |
| 4 | Total antioxidant assay | Trolox | 3.26 ± 1.7 | 3.89 ± 0.5 | 0.6 |
| 5 | Hypochlorous scavenging activity | Ascorbic acid | 87.72 ± 4.9 | 124.03 ± 9.1 | 0.009 |
| 6 | Hydroxyl radical | Mannitol | 332.93 ± 3.5 | 124.75 ± 5.8 | 0.00001 |
| 7 | Nitric oxide | Curcumin | 109.60 ± 6.1 | 58.86 ± 7.5 | 0.0028 |
| 8 | Peroxynitrite radical | Gallic acid | 591.65 ± 13.9 | 500 ± 12.2 | 0.003 |
| 9 | Erythrocyte membrane stabilizing activity | Quercetin | 94.74 ± 5.5 | 152.48 ± 4.9 | 0.0008 |
| 10 | Fe chelation | EDTA | 25.37 ± 3.5 | 118.771 ± 12.4 | 0.0062 |
Comparision of body and liver weight of CCl4 induced with control (untreated), LFE treated and silymarin treated groups
| Parameters (units) | Control | CCl4 | Sylimarin | LFE Low Dose (100 mg/kg body weight) | LFE High Dose (250 mg/kg body weight) |
|---|---|---|---|---|---|
| Initial body weight (g) | 21.70 ± 0.48 | 22.31 ± 0.26 | 22.37 ± 0.46 | 22.03 ± 0.46 | 22.07 ± 0.71 |
| Final body weight (g) | 23.28 ± 0.42 | 20.81 ± 0.74 | 23.31 ± 0.39 | 22.38 ± 0.70 | 22.17 ± 0.66 |
| Body weight change (%) | 6.79 | 6.74 | 4.20 | 1.59 | 0.45 |
| Liver weight (g) | 4.86 ± 0.11 | 5.46 ± 0.09 | 4.59 ± 0.22 | 5.03 ± 0.14 | 4.90 ± 0.08 |
| Relative liver weight (g) | 20.88 | 26.24 | 19.69 | 22.48 | 22.10 |
Extent of variation(s) in biochemical and enzymatic parameters in different groups treated with CCl4 or silymarin or LFE. The data represents mean ± SD of six independent observations
| Parameters (Units) | Control | CCl4 | Silymarin | LFE (Low Dose) | LFE (High Dose) |
|---|---|---|---|---|---|
| ALP (K.A.) | 7.75 ± 0.17 | 28.52 ± 1.87 ** | 10.50 ± 1.61 NS | 18.48 ± 1.33 ** | 12.99 ± 0.22 ** |
| ACP (K.A.) | 4.06 ± 0.48 | 7.35 ± 0.11 ** | 16.55 ± 0.43 ** | 14.35 ± 0.34 *** | 10.79 ± 0.50 ** |
| AST (u/ml) | 61.78 ± 2.48 | 133.21 ± 3.94*** | 75.26 ± 3.29 | 126.27 ± 2.73 | 86.12 ± 4.29 |
| ALT (u/ml) | 51.27 ± 1.58 | 138.29 ± 4.83 | 68.28 ± 3.97 | 109.93 ± 3.75 | 81.28 ± 4.17 |
| Protein (g/dl) | 7.61 ± 0.27 | 4.42 ± 0.30 * | 7.40 ± 0.30 NS | 4.74 ± 0.10 ** | 5.50 ± 0.19 * |
N.S. P > 0.05 When compared with control, *P < =0.05 When compared with control, ** P < =0.01 When compared with control, *** P < =0.001 When compared with control
Fig. 2Hepatoprotective effect of Lagerstroemia flower extract (LFE) or silymarin (SYL) in CCl4 treated mice. a Protective effect of LFE on catalase (CAT) activity, reduced glutathione (GSH) and Lipid peroxidation (LPO) in CCl4 treated mice. b Protective effect of silymarin on catalase (CAT) activity, reduced glutathione (GSH) and Lipid peroxidation (LPO) in CCl4 treated mice group. Comparisons were made with (i) control (CON); (ii) CCl4 treated (no protection) (CON) for statistical inference (‘t’ test for paired comparison) to interpret significant difference (Data represented as Mean ± SD of six observations. *, p < 0.05, **, p < 0.01 and ***, p < 0.001.)
Fig. 3Photomicrographs: histological sections of mice liver samples. Pictures were taken under original magnification of 400X. a Liver section from the control group demonstrating normal liver architecture with intact nucleus (IN), and normal sinusoids (NS); b Liver section from CCl4 induced damaged liver demonstrating highly deformed liver architecture with round congested portal vein (PV), bile duct proliferation (BdP), fatty lesion due to intensive fatty infiltration (FI), sign of necrosis (N), dilated sinusoid (SD), leukocyte infiltration (LI); c Liver section from CCl4 induced damaged liver demonstrating fibrosis (FB); d Liver section from Silymerin treated group demonstrating improved hepato-cellular architecture with normal sinusoids and intact nucleus (IN); e Liver section from low dose LFE (100 mg/kg of body weight) treated group showing sign of necrosis (N) [of lesser degree compared to the CCl4 group]; f Liver section from high dose LFE (250 mg/kg of body weight) treated group showing improved liver architecture with normal sinusoids (NS) and intact nucleus (IN)
Phytochemicals identified in the ethanolic extract of the flower of L.speciosa by GC-MS analysis
| Sl. No. | Compound name | Chemical formula | RT |
|---|---|---|---|
| 1. | 2,6-Nonadienal, 3,7-dimethyl- | C11H18O | 5.60 |
| 2. | N-[4-(4-Chlorophenyl)isothiazol-5-yl)-1-methylpiperidin-2-imine | C15H16ClN3S | 5.84 |
| 3. | 2-Furancarboxaldehyde, 5-methyl- | C6H6O2 | 6.77 |
| 4. | Formamide, N-[1-[(1-cyano-2-methylpropyl) hydroxyamino]-2-methylpropyl]- | C10H19N3O2 | 6.94 |
| 5. | Oxazolidine, 2,2-diethyl-3-methyl- | C8H17NO | 6.74 |
| 6. | Oxirane, [(hexadecyloxy)methyl]- | C19H38O2 | 9.27 |
| 7. | 2H-Tetrazole, 2-(1,3-dioxolan-4-ylmethyl)- | C6H10N4O2 | 9.76 |
| 8. | Furylhydroxymethyl ketone | C6H6O3 | 9.94 |
| 9. | 2,3-Dimethylfumaric acid | C6H8O4 | 10.46 |
| 10. | 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl- | C6H8O4 | 11.63 |
| 11. | 2-Furanone, 3,4-dihydroxytetrahydr | C4H6O | 12.96 |
| 12. | d-Ribo-hexos-3-ulose | C6H10O6 | 13.62 |
| 13. | 5-Hydroxymethylfurfural | C6H6O3 | 13.97 |
| 14. | d-Mannose | C6H12O6 | 14.89 |
| 15. | Tetradecanoic acid, 2-hydroxy- | C14H28O3 | 15.25 |
| 16. | 5-(Hydroxymethyl)-2-(dimethoxymethyl) furan | C8H12O4 | 15.87 |
| 17. | 1,2,3-Benzenetriol (Pyrogallol) | C6H6O3 | 17.93 |
| 18. | Desulphosinigrin | C10H17NO6S | 19.49 |
| 19. | D-Allose | C6H12O6 | 20.64 |
| 20. | 3-tert-Butyl-4-hydroxyanisole (also known as 3-BHA, which is a potent antioxidant) | C11H16O2 | 22.66 |
| 21. | Benzoic acid, 4-hydroxy-3,5-dimethoxy- (also known as Syringic acid) | C9H10O5 | 28.09 |
| 22. | n-Hexadecanoic acid | C16H32O2 | 31.03 |
| 23. | Hexadecanoic acid, ethyl ester | C18H36O2 | 31.70 |
| 24. | 9,12-Octadecadienoic acid (Z, Z)- (also known as Linoleic acid) | C18H32O2 | 34.23 |
| 25. | 9,12,15-Octadecatrienoic acid, 2,3-dihydroxypropyl ester, (Z, Z, Z)- | C21H36O4 | 34.34 |
| 26. | γ-Sitosterol | C29H50O | 52.51 |